TITLE

Reimbursement Decisions of the All Wales Medicines Strategy Group Influence of Policy and Clinical and Economic Factors

AUTHOR(S)
Linley, Warren G.; Hughes, Dyfrig A.
PUB. DATE
September 2012
SOURCE
PharmacoEconomics;2012, Vol. 30 Issue 9, p779
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: There have been several explorations of factors influencing the reimbursement decisions of the National Institute for Health and Clinical Excellence (NICE) but not of other UK-based health technology assessment (HTA) organizations. Objective: This study aimed to explore the factors influencing the recommendations of the All Wales Medicines Strategy Group (AWMSG) on the use of new medicines in Wales. Methods: Based on public data, logistic regression models were developed to evaluate the influence of cost effectiveness, the quality and quantity of clinical evidence, disease characteristics (including rarity), budget impact, and a range of other factors on the recommendations of AWMSG and its subcommittee, the New Medicines Group (NMG). Results: Multivariate analyses of 47 AWMSG appraisals between 2007-9 correctly predicted 87% of decisions. The results are suggestive of a positive influence on recommendations of the presence of probabilistic sensitivity analyses (PSAs) but, counter-intuitively, a statistically significant negative influence of evidence from high-quality randomized controlled trials (RCTs) [odds ratio 0.059; 95% CI 0.005, 0.699]. This latter observation may be attributed to our strict definition of high quality, which excluded the use of surrogate endpoints. Putative explanatory variables, including cost effectiveness, budget impact, underlying disease characteristics and 'ultra'-orphan drug status were not statistically significant predictors of final AWMSG decisions based on our dataset. Univariate analyses indicate that medicines with negative recommendations had significantly higher incremental costeffectiveness ratios than those with positive recommendations, consistent with the pursuit of economic efficiency. There is also evidence that AWMSG considers equity issues via an ultra-orphan drugs policy. Conclusions: Consideration of decision uncertainty via PSA appears to positively influence the reimbursement decisions of AWMSG. The significant negative impact of the presence of high-quality RCTs, and the lack of a significant positive impact of other expected factors, may reflect issues in the plausibility of supporting evidence for medicines that received negative recommendations. Furthermore, it serves to emphasize the difficulties in applying the usual hierarchies of evidence to the HTA process, and in particular to the appraisal of high-cost specialist medicines close to market launch.
ACCESSION #
83742266

 

Related Articles

  • Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Spinner, Daryl S.; Birt, Julie; Walter, Jeffrey W.; Bowman, Lee; Mauskopf, Josephine; Drummond, Michael F.; Copley-Merriman, Catherine // ClinicoEconomics & Outcomes Research;2013, Vol. 5, p69 

    Background: Health-technology assessment (HTA) plays an important role in informing drug-reimbursement decision-making in many countries. HTA processes for the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, the Common Drug Review (CDR) in Canada, and the National Institute for...

  • NICE: alone in Europe but not the world. Gillies, Malcolm B. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/21/2009, p429 

    No abstract available.

  • Value-Based Approaches to Healthcare Systems and Pharmacoeconomics Requirements in Asia. Kamae, Isao // PharmacoEconomics;2010, Vol. 28 Issue 10, p831 

    Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st...

  • HAS to be NICE? Pouvourville, GĂ©rard // European Journal of Health Economics;Jun2013, Vol. 14 Issue 3, p363 

    The author reflects on the changes in the regulatory environment of France following the introduction of cost-effectiveness analysis (CEA) in the pricing and reimbursement process on drugs and medical devices. He discusses the guideline for CEA published by the French National Authority for...

  • NICE result for Exogen and Watch BP Home A.  // PharmacoEconomics & Outcomes News;1/26/2013, Issue 670, p11 

    The article reports that a medical technology guidance supporting the Exogen ultrasound bone healing system and the WatchBP Home A device has been published by the National Institute for Health and Clinical Excellence (NICE) in Great Britain.

  • Proposed amendments to NICE's HTA methods criticised.  // PharmacoEconomics & Outcomes News;Oct2014, Vol. 713 Issue 1, p8 

    The article reports on commentaries published in the journal "PharmacoEconomics," which include one by Mike Paulden from University of Alberta, Edmonton, on NICE's previous amendments to its methods for health technology appraisal (HTA) and another by Suzanne R. Hill and Leslie G. Olson from...

  • New NICE report clears fog over use of drug-eluting stents in UK. Brosky, John // Medical Device Daily;2/4/2008, Vol. 12 Issue 23, p1 

    The article reports that the National Institute for Health and Clinical Excellence (NICE) in England has reversed its earlier position opposing use of drug-eluting stents (DES), clearing the way for reimbursement of such interventions. The final guidance on DES will go into effect in March 2008...

  • UK's NICE Launching System to Help Biologics Payments. Moran, Nuala // BioWorld International;12/2/2009, Vol. 14 Issue 48, p1 

    This article reports on the launch of a drug reimbursement system by the British National Institute for Health and Clinical Excellence (NICE) in 2009. According to the NICE, the system allows the reimbursement of drugs without the need to pass the cost-benefit hurdles of the body. Andrew Dillon,...

  • PharmacoEconomics issue on overcoming 'fourth hurdle' (NICE).  // PharmacoEconomics & Outcomes News;10/4/2008, Issue 563, p2 

    The article announces the publication of an issue of "PharmacoEconomics" that is devoted to helping pharmaceutical companies better understand the requirements behind the British National Institute for Health and Clinical Excellence's (NICE) requirement of demonstrating that a drug is cost...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics